The pharmaceutical company Novo Nordisk announced the top-line results from their evoke and evoke+ phase 3 trials, which tested the weight-loss drug semaglutide in people with early-stage symptomatic Alzheimers disease
Are the ratios correct
This is a drug-class mechanism, not a claim specific to any compounded formulation
Initial symptoms (prodromal phase) typically appear 1-5 days before the rash and may include: Tingling, burning, or shooting pain in a specific area of skin, usually on one side of the body Heightened skin sensitivity (hyperaesthesia) in the affected area Headache, fatigue, or general malaise Fever or chills in some cases Itching or numbness in the area where the rash will appear The characteristic rash develops in distinct stages: Red patches appear on one side of the body, typically following a dermatomal distribution (the area supplied by a single nerve root) Fluid-filled blisters (vesicles) develop within the red patches over 3-5 days Blisters become cloudy , then crust over and scab within 7-10 days Complete healing typically occurs within 2-4 weeks Common locations include the torso (chest or abdomen), face (particularly around one eye), or neck, though shingles can affect any area supplied by sensory nerves
This is the primary difference from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP)
They could show beneficial effects of three gliptins (sita-, saxa-, and vildagliptin) in lowering HbA1c also in patients with longstanding T2DM for more than 10 years
